Teva Pharmaceutical made $4.395 billion last quarter and expects more sales for the whole year.

Nov 3, 2026, 11:17 AM ETResultsRead the original at globenewswire.com

Good for TEVA

Teva raised its 2026 sales and adjusted profit forecasts as AUSTEDO, AJOVY, and UZEDY grew. Global generics sales fell, but the higher forecast and newer-drug growth point to improvement.

TEVA · Teva Pharmaceutical Industries Ltd.

AI read · Good for TEVA

The AI's read

Growth in newer medicines and the higher company forecast support stronger business prospects. Biosimilars may reach a sales goal a year early, and credit ratings rose to investment grade. Global generics sales fell, but Teva still raised its full-year forecast.

Get alerts for TEVA

Follow Teva Pharmaceutical Industries Ltd. (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TEVA

Free on the App Store and Google Play, or on the web.